This FOA encourages applications for research projects that identify, validate and/or functionally characterize loci, genetic variations and haplotypes that are associated with vulnerability to addiction and that potentially inform the likelihood of responsiveness to treatment. Applications that propose to examine intermediate phenotypes or endophenotypes to assess the molecular genetics of drug addiction, addiction vulnerability and/or their associated co-morbidities and how they are related to drug addiction are especially encouraged. Also encouraged are genetic as well as computational and large-scale genomic approaches, which may include but are not limited to linkage, linkage disequilibrium, case-control or family-based studies, and integration of data from other databases that may supplement substance abuse genetics and genomics data. Data may be collected from the general population, special populations, recent admixed populations, and/or animal models. Secondary data analysis of data collected from the general population, special populations, recent admixed populations, and/or animal models is also appropriate for this announcement. Investigators are encouraged to include functional characterization, gene x gene interactions, gene x environment interactions, gene x environment x development interactions, pharmacogenetics, and non-human models, as appropriate.
Deadlines:
PA-17-120 Expiration Date January 8, 2020
